Cell-bound complement activation products
Cell-Bound Complement Activation Products (CB-CAPs) or complement split products, refers to complement activation fragments, C4d, that are bound covalently to somatic cells, as a result of activation of the classical complement pathway.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Cell-Bound Complement Activation Products (CB-CAPs) or complement split products, refers to complement activation fragments, C4d, that are bound covalently to somatic cells, as a result of activation of the classical complement pathway. They appear potentially useful for the diagnosis of systemic lupus erythematosus as of 2015.
Medical use
CB-CAPs can be used in the diagnosis and monitoring of SLE. Their efficacy is aided by the ability to be measured throughout the lifespans of erythrocytes, b-lymphocytes.
Research
Research into the development of CB-CAPs has been advocated by the Lupus Foundation of America.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1316685770 under CC BY-SA 4.0; modifications have been made.